BAYER FAILED TO REVEAL TRASYLOL RISK STUDY

James Sabatini

Contributor

0 CommentsPrint ArticleSubscribe

The F.D.A. announced that Bayer A.G., failed to reveal to federal drug officials the results of a large study suggesting that Trasylol might increase the risks of death and stroke. The F.D.A. recently announced that Trasylol may increase the chance for death, serious kidney damage, congestive heart failure and strokes.

The F.D.A. only found out about the Trasylol study after getting a tip from a researcher involved in the study. Bayer's eplanation for not disclosing the study and its results - it mistakenly failed to inform the F.D.A. Certain FDA officials were shocked that Bayer neglected to inform them of the study. This recent study is another piece of evidence pointing to serious dangers and risks with taking Trasylol. In January, an article published in the New England Journal of Medicine, found that Trasylol increased the risks of kidney failure, stroke and heart attack. The article's author opined that stopping the drug's use would prevent 10,000 to 11,000 kidney failures per year.